Mitochondrial dysfunction, characterized by the electron transport chain (ETC) leakage and reduced adenosine tri-phosphate synthesis, occurs primarily due to free radicals -induced mutations in either the mitochondrial deoxyribonucleic acid (mtDNA) or nuclear (n) DNA caused by pathogenic infections, toxicant exposures, adverse drug-effects, or other environmental exposures, leading to secondary dysfunction affecting ischemic, diabetic, cancerous, and degenerative diseases. In these concerns, mitochondria-targeted remedies may include a significant role in the protection and treatment of mitochondrial function to enhance its activity. Coenzyme Q10 pyridinol and pyrimidinol antioxidant analogues and other potent drug-compounds for their multifunctional radical quencher and other anti-toxic activities may take a significant therapeutic effectivity for ameliorating mitochondrial dysfunction. Moreover, the encapsulation of these bioactive ligands-attached potent compounds in vesicular system may enable them a superb biological effective for the treatment of mitochondria-targeted dysfunction-related diseases with least side effects. This review depicts mainly on mitochondrial enzymatic dysfunction and their amelioration by potent drugs with the usages of nanoparticulated delivery system against mitochondria-affected diseases.
Mitochondrial diseases. MeSH. Bethesda, MD: National Center for Biotechnology Information (Retrieved 2 August 2019).
2.
ScharfeCLuHHNeuenburgJK, et al.Mapping gene associations in human mitochondria using clinical disease phenotypes. In: RzhetskyAA (ed), 5(4), 2009.Plos Comput Biol.
3.
KerrDS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab2010; 99(3): 246–255.
VentoJMPappaB. Genetic counseling in mitochondrial disease. Neurotherapeutics2013; 10(2): 243–250.
6.
SanaSGhoshSDasN, et al.Vesicular melatonin efficiently downregulates sodium fluoride-induced rat hepato-and broncho- TNF-α, TGF-β expressions, and associated oxidative injury: A comparative study of liposomal and nanoencapsulated forms. Int J Nanomed2017; 12: 4059–4071.
7.
GhoshDChoudhurySTGhoshS, et al.Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact2012; 195: 206–214.
8.
GhoshASarkarSMandalAK, et al.Neuroprotective role of nanocapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One2013; 8(4): e57735.
9.
GhoshSDungdungSRChoudhuryST, et al.Encapsulation of the flavonoid quercetin with an arsenic chelator into nanocapsules enables the simultaneous delivery of hydrophobic and hydrophilic drugs with a synergistic effect against chronic arsenic accumulation and oxidative stress. Free Radic Biol Med2011; 51: 1893–1902.
10.
GhoshSSarkarSChoudhuryST, et al.Triphenyl phosphonium coated nano-quercetin for oral delivery: Neuroprotective effects in attenuating age related global moderate cerebral ischemia reperfusion injury in rats. Nanomed Nanotechnol Biol Med2017; 13(8): 2439–2450.
11.
ArmstrongJSKhdourOMHechtSM. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J2010; 24(7): 2152–2163.
12.
MarkesberyWRCarneyJM. Oxidative alterations in Alzheimer's disease. Brain Pathol1999; 9(1): 133–146.
13.
BarnhamKJMastersCLBushAI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov2004; 3(3): 205–214.
14.
CalabreseVLodiRTononC, et al.Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci2005; 233(1–2): 145–162.
15.
LinMTBealMF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature2006; 443(7113): 787–795.
16.
CampuzanoVMonterminiLMoltoMD, et al.Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science1996; 271(5254): 1423–1427.
17.
CampuzanoVMonterminiLLutzY, et al.Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet1997; 6(11): 1771–1780.
18.
BidichandaniSIAshizawaTPatelPI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet1998; 62(1): 111–121.
SakamotoNOhshimaKMonterminiL, et al.Sticky DNA, a self-associated complex formed at long GAA*TTC repeats inn intron 1 of the frataxin gene, inhibits transcription. J Biol Chem2001; 276(29): 27171–27177.
21.
KoutnikovaHCampuzanoVKoenigM. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum Mol Genet1998; 7(9): 1485–1489.
22.
CondoIVenturaNMalisanF, et al.vivo maturation of human frataxin. Hum Mol Genet2007; 16(13): 1534–1540.
23.
BabcockMde SilvaDOaksR, et al.Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science1997; 276(5319): 1709–1712.
24.
MuhlenhoffURichhardtNRistowM, et al.The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet2002; 11(17): 2025–2036.
25.
YoonTCowanJA. Iron-sulfur cluster biosynthesis, Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc2003; 125(20): 6078–6084.
26.
DelatyckiMBCamakarisJBrooksH, et al.Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neural1999; 45(5): 673–675.
27.
LushchakOVPiroddiMGalliF, et al.Aconitase post-translational modification as a key in linkage between krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species. Redox Rep2014; 19(1): 8–15.
28.
KumarADhullDKMishraPS. Therapeutic potential of mGluR5 targeting in Alzheimer's disease. Front Neurosci2015; 9: 215.
29.
Alzheimer'sA.. Alzheimer's disease facts and figures. Alzheimers Dement2015; 11: 332–384.
SwerdlowRHBurnsJMKhanSM. The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta2014; 1842: 1219–1231.
32.
DavisJNHunnicuttEJChisholmJC. A mitochondrial bottleneck hypothesis of Alzheimer's disease. Mol Med Today1995; 1: 240–247.
33.
ReddyPHBealMF. Amyloid β, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med2008; 14: 45–53.
34.
ReddyPHManczakMMaoP, et al.Amyloid-β and mitochondria in aging and Alzheimer's disease: Implications for synaptic damage and cognitive decline. J Alzheimers Dis2010; 20: S499–S512.
35.
CalkinsMJManczakMMaoP, et al.Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet2011; 20: 4515–4529.
36.
WenerCJHeyney-von HaussenRMallG, et al.Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci2008; 6: 8.
37.
KnaryanVHSamantaraySLeGelC, et al.Tracking extranigral degeneration in animal models of Parkinson's disease: Quest for effective therapeutic strategies. J Neurochem2011; 118: 326–338.
38.
WaltersE. Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat Disord2009; 15(3): S6–S12.
39.
KalaitzakisMEGraeberMBGentlemanSM, et al.Parkinson disease: Extranigral, multisystem, and {alpha}-synuclein "plus. Arch Neurol2009; 66: 914–915.
40.
ChouKLTaylorJLPatilPG. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord2013; 19(11): 966–969.
41.
MandemakersWMoraisVADe StrooperB. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cel Sci2007; 120: 1707–1716.
42.
ParkerWDJSwerdlowRH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet1998; 62: 758–762.
43.
TaylorRWTurnbullDM. Mitochondrial DNA mutations in human disease. Nat Rev Genet2005; 6(5): 389–402.
44.
ButterfieldDA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neuridegeneration in Alzheimer’s disease brain. A review. Free Radic Res2002; 36(12): 1307–1313.
45.
BayevaMGheorghiadeMArdehaliH. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol2013; 61(6): 599–610.
46.
MoreiraPIZhuXWangX, et al.Mitochondria: A therapeutic target in neurodegeneration. Biochim Biophys Acta2010; 1802(1): 212–220.
47.
WeissigVBoddapatiSVJabrL, et al.Mitochondria specific nanotechnology. Nanomedicine (Lond)2007; 2(3): 275–285.
48.
WaltersAMPorterGAJrBrookesPS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res2012; 111(9): 1222–1236.
49.
JoinerMLKovalOMLiJ, et al.CaMKII determines mitochondrial stress responses in heart. Nature2012; 491(7423): 269–273.
50.
SzetoHHSchillerPW. Novel therapies targeting inner mitochondrial membrane from discovery to clinical development. Pharm Res2011; 28(11): 2669–2679.
51.
PradelliLABeneteauMRicciJE. Mitochondrial control of caspase-dependent and –independent cell death. Cell Mol Life Sci2010; 67(10): 1589–1597.
52.
KinnallyKWPeixotoPMRyuSY, et al.Is mPTP the gatekeeper for necrosis, apoptosis, or both?Biochim Biophys Acta2011; 1813(4): 616–622.
53.
DareAJBoltonEAPettigrewGJ, et al.Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant Mito Q. Redox Biol2015; 5: 163–168.
54.
Modica-NapolitanoJSSinghKK. Mitochondrial dysfunction in cancer. Mitochondrion2004; 4(5–6): 755–762.
55.
GalluzziLMorselliEKeppO, et al.Mitochondrial gateways to cancer. Mol Asp Med2010; 31(1): 1–20.
56.
GogvadzeVOrreniusSZhivotovskyB. Mitochondria in cancer cells: What is so special about them?Trends Cel Biol2008; 18(4): 165–173.
57.
WangGLSemenzaGL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA1993; 90(9): 4304–4308.
KulawiecMOwensKMSinghKK. Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther2014; 8(14): 1378–1385.
60.
UmHD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: A review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget2016; 7(5): 5193–5203.
61.
LowellBBShulmanGI. Mitochondrial dysfunction and type-2 diabetes. Science2005; 307(5708): 384–387.
62.
RitovVBMenshikovaEVHeJ, et al.Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes2005; 54(1): 8–14.
63.
AouscheriOSakaSKrimM, et al.The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes2015; 39(1): 44–49.
64.
ZhaoKZhaoGMWuD, et al.Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem2004; 279(33): 34682–34690.
65.
ChanDC. Mitochondria: Dynamic organelles in disease, aging, and development. Cell2006; 125: 1241–1252.
66.
SarkarSMandalA. Neurophysiological changes in oxidative injury: Involvement of calcium homeostasis and ER stress. JSM Alzheimer's Dis Relat Dement2017; 4(1): 1033.
67.
WallaceDCSinghGLottMT, et al.Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science1988; 242(4884): 1427–1430.
68.
PenneyJBJYoungAB. GABA as the pallidothalamic neutransmitter: Implications for basal ganglia function. Brain Res1981; 207(1): 195–199.
69.
MattsonMPSonTGCamandolaS. Viewpoint: Mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose-Response2007; 5(3): 174–186.
70.
OrreniusSGogvadzeVZhivotovskyB. Mitochondrial oxidative stress: Implications for cell death. Annu Rev Pharmacol Toxicol2007; 47: 143–183.
71.
MandalAKGhoshADasN. Vesicular drug targeting in combating cerebral oxidative injury. Ind J Appl Res2018; 8(1): 287–292.
72.
MatesJMPerez-GomezCNunezde CastroI. Antioxidant enzymes and human diseases. Clin Biochem1999; 32(8): 595–603.
73.
FridovichI. Fundamental aspects of reactive oxygen species, or what's the matter with oxygen?Ann N Y Acad Sci1999; 893: 13–18.
74.
SeviddioGBellantiFRomanoAD, et al.Bioenergetics in aging: Mitochondrial proton leak in aging rat liver, kidney and heart. Redox Rep2007; 12(1): 91–95.
75.
MandalAK. Hydroxyapatite nanoparticles as delivery system in combating various diseases. Int J Curr Adv Res2018; 7(10): 15869–15877.
76.
MandalAK. Vesicular drug delivery against leishmaniasis in animals: A critical evaluation. Int J Curr Res2018; 10(1): 64103–64113.
77.
AlamMPKhdourOMArcePM, et al.Cytoprotective pyridinol antioxidants as potential therapeutic agents for neurodegenerative and mitochondrial diseases. Bioorg Med Chem2014; 22(17): 4935–4947.
78.
KhdourOMBandopadhyayIVisavadiyaNP, et al.Phrnothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells. Med Chem Commun2018; 9: 1491–1501.
79.
DuveauDYArcePMSchoenfeldRA, et al.Synthesis and characterization of mito Q and idebenone analogues as mediators of oxygen consumption in mitochondria. Bioorg Med Chem2010; 18(17): 6429–6441.
80.
TrnkaJElkalafMAndelM. Lipophilic triphenylphosphonium cations inhibit mitochondrial electron transport chain and induce mitochondrial proton leak. PLoS ONE2015; 10(4): e0121837.
81.
HortonKLStewartKMFonsecaSB, et al.Mitochondria penetrating peptides. Chem Biol2008; 15(4): 375–382.
82.
SzetoHHBirkAV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther2014; 96(6): 672–683.
83.
LeeBROhKTOhYT, et al.A novel pH-responsive polysaccharide ionic complex for proapoptotic D-(KLAKLAK)2 peptide delivery. Chem Commun (Camb)2011; 47(13): 3852–3854.
84.
JiangLLiLHeX, et al.Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomater2015; 52: 126–139.
85.
LiLGeislerIChmielewskiJ, et al.Cationic amphiphilic polyproline helix P11LRR targets intracellular mitochondria. J Control Release2010; 142(2): 259–266.
86.
YamadaYAkitaHKamiyaH, et al.MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta2008; 1778(2): 423–432.
87.
YamadaYFukudaYHarashimaH. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles. Mitochondrion2015; 24: 50–55.
88.
BiswasSTorchillinVP. Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev2014; 66: 26–41.
89.
MurphyMP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol1997; 15(8): 326–330.
90.
VestweberDSchatzG. DNA-protein conjugates can enter mitochondria via rhe protein import pathway. Nature1989; 338(6211): 170–172.
91.
ChretienDBenitPHaHH, et al.Mitochondria are physiologically maintained at close to 50◦C. Plos Biol2018; 16: e2003992.
92.
WangDQHuangHZhouMX, et al.A thermoresponsive nanocarrier for mitochondria-targeted drug delivery. Chem Commun2019; 55: 4051–4054.
93.
WangDZhouMHuangH, et al.Gold nanoparticle-based probe for analyzing mitochondrial temperature in living cells. ACS Appl Biomater2019; 2(8): 3178–3182.
94.
GuoXWeiXChenZ, et al.Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy. Prog Mater Sci2020; 107: 100599.
95.
ZielonkaJJosephJSikoraA, et al.Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev2017; 117(15): 10043–10120.
96.
YuanPMaoXWuX, et al.Mitochondria-targeting, intracellular delivery of native proteins using biodegradable silica nanoparticles. Angew Chem Int Ed2019; 58(23): 7657–7661.
97.
KolbergAWenzelCHackenstrassK, et al.Opposing temperature dependence of the stretching response of single PEG and PNiPAM polymers. J Am Chem Soc2019; 141(29): 11603–11613.
98.
GaoHBiYChenJ, et al.Near-infrared light-triggered switchable nanoparticles for targeted chemo/photothermal cancer therapy. ACS Appl Mater Inter2016; 8(24): 15103–15112.
99.
QinYPChenJBiY, et al.Near-infrared light remote-controlled intracellular anti-cancer drug delivery using thermo/pH sensitive nanovehicle. Acta Biomater2015; 17: 201–209.
100.
ZuoHD. iRGD: A promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J Oncol2019; 2019: 9367845–9367915.
101.
ZhouMXHuangHWangDQ, et al.Light-triggered PEGylation/dePEGylation of the nanocarriers for enhanced tumor penetration. Nano Lett2019; 19(6): 3671–3675.
102.
WangZJKuangXShiJ, et al.Targeted delivery of geranylgeranylacetone to mitochondria by triphenylphosphonium modified nanoparticles: A promising strategy to prevent aminoglycoside-induced hearing loss. Biomater Sci2017; 5(9): 1800–1809.
103.
WangZGuoWKuangX, et al.Nanopreparations for mitochondria targeting drug delivery system: Current strategies and future prospective. Asian J Pharmaceut Sci2017; 12: 498–508.
104.
LiQHuangY. Mitochondrial targeted strategies and their application for cancer and other diseases treatment. J Pharmaceut Investig2020; 50: 271–293.
105.
KhdourOMArcePMRayB, et al.An optimized pyrimidinol multifunctional radical quencher. ACS Med Chem Lett2013; 4(8): 724–729.
106.
WangFOgasawaraMAHuangP. Small mitochondria-targeting molecules as anti-cancer agents. Mol Asp Med2010; 31: 75–92.
107.
SmithRAPorteousCMCoulterCV, et al.Selective targeting of an antioxidant to mitochondria. Eur J Biochem1999; 263: 709–716.
108.
JamesAMSharpleyMSManasAR, et al.Interaction of the mitochondria-targeted antioxidant Mito Q with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem2007; 282(20): 14708–14718.
109.
JamesAMCochemeHMSmithRA, et al.Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species, Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem2005; 280: 21295–21312.
110.
MuratovskaALightowlersRNTaylorRW, et al.Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: Implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res2001; 29(9): 1852–1863.
111.
LibermanEATopalyVPTsofinaLM, et al.Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature1969; 222: 1076–1078.
112.
MurphyMPSmithRA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Ann Rev Pharmacol Toxicol2007; 47: 629–656.
113.
RossMFKelsoGFBlaikieFH, et al.Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochem Biokhim2005; 70(2): 222–230.
114.
ModicaNJSAprilleJR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev2001; 49: 63–70.
WeissigVLaschJErdosG, et al.DQAsomes: A novel potential drug and gene delivery system made from dequaliniumTM. Pharm Res1998; 15(2): 334–337.
117.
D’SouzaGGMRammohanRChengSM, et al.DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release2003; 92(1–2): 189–197.
118.
S’SouzaGGBoddapatiSVWeissigV. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion2005; 5(5): 352–358.
119.
HegartyJPKrzeminskiJSharmaAK, et al.Bolaamphiphile-based nonocomplex delivery of phosphorothiolate gapmer antisense oligonucleotides as a treatment for Clostridium difficile. Int J Nanomed2016; 11: 3607–3619.
120.
D’SouzaGGMChengSMBoddapatiSV, et al.Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxal. J Drug Target2008; 16(7–8): 578–585.
121.
ZupancicSKocbekPZariwalaMG, et al.Design and development of novel mitochondrial targeted nanocarriers, DQAsomes for curcumin inhalation. Mol Pharm2014; 11(7): 2334–2345.
122.
GuoFYuMWangJ, et al.The mitochondria-targeted and IR780-regulated theranosomes for imaging and enhanced photodynamic/photothermal therapy. RSC Adv2016; 6(14): 11070–11076.
123.
BoddapatiSVD’SouzaGGErdoganS, et al.Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett2008; 8(8): 2559–2563.
124.
PatelNRHatziantoniouSGeorgopoulasA, et al.Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res2010; 20(3): 244–249.
125.
BiswasSDodwadkarNSDeshpandePP, et al.Liposomes loaded with paclitaxel and modified with novel triphenyl phosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release2012; 159(3): 393–402.
126.
KatagiriKArigaKKikuchiJI. Preparation of organic-inorganic hybrid vesicle “cerasome” derived from artificial lipid with alkoxysilyl head. Chem Lett1999; 28(7): 661–662.
127.
WangYWangBLiaoH, et al.Liposomal nanohybrid cerasomes for mitochondria-targeted drug delivery. J Mater Chem B2015; 3(36): 7291–7299.
128.
TuoJXieYSongJ, et al.Development of a novel berberine-mediated mitochondria-targeting nanoplatform for drug-resistant cancer therapy. J Mater Chem B2016; 4(42): 6856–6864.
129.
KhalilIAKogureKFutakiS, et al.High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem2006; 281(6): 3544–3551.
130.
YamadaYFurukawaRYasuzakiY, et al.Dual function MITO-Porter, a nanocarrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol Ther2011; 19(8): 1449–1456.
131.
YamadaYHarashimaH. Rnhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposome based nanocarrier. Mitochondrion2013; 13(5): 526–532.
132.
KawamuraEYamadaYHarashimaH. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter. Mitochondrion2013; 13(6): 610–614.
133.
FurukawaRYamadaYKawamuraE, et al.Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria. Biomater2015; 57: 107–115.
134.
YamadaYNakamuraKAbeJ, et al.Mitochondrial delivery of coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. J Control Release2015; 213: 86–95.
135.
FarokhzadOCLangerR. Impact of nanotechnology on drug delivery. ACS Nano2009; 3(1): 16–20.
136.
MarracheSPathakRKDarleyKL, et al.Nanocarriers for tracking and treating diseases. Curr Med Chem2013; 20(28): 3500–3514.
137.
KamalyNXiaoZValenciaPM, et al.Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev2012; 41(7): 2971–3010.
138.
ZhangLGuFXChanJM, et al.Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther2008; 83(5): 761–769.
139.
SharmaASolimanGMAl-HajajN, et al.Design and evaluation of multifunctional nanocarriers for selective delivery of coenzyme Q10 to mitochondria. Biomacromolecules2012; 13(1): 239–252.
140.
YueCYangYZhangC, et al.ROS-responsive mitochondria-targeting blended nanoparticles: Chemo and photodynamic synergistic therapy for lung cancer with on-demand drug release upon irradiation with a single light source. Theranostics2016; 6(13): 2352–2366.
141.
HouJYuXShenY, et al.Triphenyl phosphine-functionalized chitosan nanoparticles enhanced antitumor efficiencythrough targeted delivery of doxorubicin to mitochondria. Nanoscale Res Lett2017; 12(1): 158.
142.
PalazzoBIafiscoMLaforgiaM, et al.Biomimetic hydroxyapatite-drug nanocrystals as potential bone substitutes with antitumor drug delivery properties. Adv Funct Mater2007; 17(13): 2180–2188.
143.
YuanYLiuCQianJ, et al.Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomater2010; 31(4): 730–740.
144.
XuJXuPLiZ, et al.Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in C6 cells. J Biomed Mater Res A2012; 100(3): 738–745.
145.
XiongHDuSNiJ, et al.Mitochondria and nuclei dual-targeted heterogenous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin. Biomater2016; 94: 70–83.
146.
KwonHJChaMYKimD, et al.Mitochondria-targeting ceria nanoparticles as anti-oxidants for Alzheimer’s disease. ACS Nano2016; 10(2): 2860–2870.
147.
QuQMaXZhaoY. Anticancer effect of alpha-tocopheryl succinate delivered by mitochondria-targeted mesoporous silica nanoparticles. ACS Appl Mater Inter2016; 8(50): 34261–34269.
148.
LuoGFChenWHLiuY, et al.Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide. Sci Rep2014; 4: 6064.
149.
LiLSunWLiL, et al.A pH-responsive sequential-disassembly nanohybrid for mitochondrial targeting. Nanoscale2017; 9(1): 314–325.
150.
MandalAK. Mesoporius silica nanoparticles as delivery system against diseases. Int J Recent Sci Res2018; 9(9C): 28817–28825.
151.
GalluzziLLarochetteNZamzamiN, et al.Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene2006; 25(34): 4812–4830.
152.
ZhangXChibliHMielkeR, et al.Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. Bioconjug Chem2011; 22(2): 235–243.
153.
KneippJKneippHMcLaughlinM, et al.vivo molecular probing of cellular compartments with gold nanoparticles and nanoaggregates. Nano Lett2006; 6(10): 2225–2231.
154.
MaXWangXZhouM, et al.A mitochondria-targeting gold-peptide nanoassembly for enhanced cancer-cell killing. Adv Healthc Mater2013; 2(12): 1638–1643.
155.
MandalAK. Gold nanomaterials as drug delivery system against diseases. Ann Res Rev Biol2017; 19(6): 37866–37867.
156.
CostantiniPJacototEDecaudinD, et al.Mitochondrion as a novel target of anticancer chemotherapy. J Nat Cancer Inst2000; 92: 1042–1053.
MurphyMP. Antioxidants as therapies: Can we improve on nature?Free Radic Biol Med2014; 66: 20–23.
159.
LotitoSBFreiB. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: Cause, consequence, or epiphenomenon?Free Radic Biol Med2006; 41: 1727–1746.
160.
ChamberlainGRTulumelloDVKelleySO. Targeted delivery of doxorubicin to mitochondria. ACS Chem Biol2013; 8(7): 1389–1395.
161.
FonsecaSBPereiraMPMourtadaR, et al.Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chem Biol2011; 18(4): 445–453.
162.
HuQGaoMFengG, et al.Mitochondria-targeted cancer therapy using a light-up probe with aggregation-induced-emission characteristics. Angew Chem Int Ed2014; 53: 14225–14229.
163.
DongLFJamesonVJTillyD, et al.Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy. Free Radic Biol Med2011; 50: 1546–1555.
164.
MillardMGallagherJDOlenyukBZ, et al.A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J Med Chem2013; 56(22): 9170–9179.
165.
XingLLyuJYYangY, et al.pH-responsive de-PEGylated nanoparticles based on triphenylphosphine-quercetin self-assemblies for mitochondria-targeted cancer therapy. Chem Commun (Camb)2017; 53: 8790–8793.
166.
BattogtokhGKoYT. Mitochondrial-targeted photosensitizer-loaded folate-albumin nanoparticle for photodynamic therapy of cancer. Nanomed2017; 13: 733–743.
167.
LeiWXieJHouY, et al.Mitochondria-targeting properties and photodynamic activities of porphyrin derivatives bearing cationic pendant. J Photochem Photobiol B2010; 98: 167–171.
168.
SongYFLiuDZChengY, et al.Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity. Sci Rep2015; 5: 16125.
169.
WangJFanXYYangLY, et al.Conjugated 5-fluorouracil with mitochondria targeting lipophilic cation: Design, synthesis and biological evaluation. Med Chem Comm2016; 7: 2016–2019.
170.
ChengGZielonkaJMcAllisterD, et al.Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism. Cancer Lett2015; 365: 96–106.
171.
ChengGZielonkaJDrankaBP, et al.Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res2012; 72(10): 2634–2644.
172.
ChengGZielonkaJMcAllisterDM, et al.Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer2013; 13: 285.
173.
JainMRiveraSMonclusEA, et al.Mitochondrial reactive oxygen species regulate transforming growth factor-β signaling. J Biol Chem2013; 288(2): 770–777.
174.
StarenkiDParkJI. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J Clin Endocrinol Metab2013; 98: 1529–1540.
175.
BurnsRJSmithRAMurphyMP. Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch Biochem Biophys1995; 322: 60–68.
176.
CraneFL. Hydroquinone dehydrogenases. Ann Rev Biochem1977; 46: 439–469.
KelsoGFPorteousCMCoulterCV, et al.Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem2001; 276(7): 4588–4596.
179.
DashdorjAJyothiKRLimS, et al.Mitochondria-targeted antioxidant Mito Q ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med2013; 11: 178.
180.
GaneEJWeilertFOrrDW, et al.The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int2010; 30: L1019–L1026.
181.
GrahamDHuynhNNHamiltonCA, et al.Mitochondria-targeted antioxidant Mito Q10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension2009; 54: 322–328.
182.
JauslinMLMeierTSmithRA, et al.Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J2003; 17: 1972–1974.
183.
LowesDAThottakamBMWebsterNR, et al.The mitochondria-targeted antioxidant Mito Q protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med2008; 45: 1559–1565.
184.
OyewoleAOWilmotMCFowlerM, et al.Comparing the effects of mitochondrial targeted and localized antioxidants with cellular antioxidants in human skin cells exposed to UVA and hydrogen peroxide. FASEB J2014; 28: 485–494.
185.
RyanBJHoekSFonEA, et al.Mitochondrial dysfunction and mitophagy in Parkinson's: From familial to sporadic disease. Trends Biochem Sci2015; 40: 200–210.
186.
SnowBJRolfeFLLockhartMM, et al.A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant Mito Q as a disease-modifying therapy in Parkinson's disease. Mov Disord2010; 25(11): 1670–1674.
187.
FinichiuPGLarsenDSEvansC, et al.A mitochondria-targeted derivative of ascorbate: Mito C. Free Radic Biol Med2015; 89: 668–678.
188.
JamesonVJCochemeHMLoganA, et al.Synthesis of triphenylphosphonium vitamin E derivatives as mitochondria-targeted antioxidants. Tetrahedron2015; 71(44): 8444–8453.
189.
HanMVakiliMRSoleymaniAH, et al.Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm2014; 11(8): 2640–2649.
190.
ZhouJZhaoWYMaX, et al.The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials2013; 34(14): 3626–3638.
191.
ChoDYChoHKwonK, et al.Triphenylphosphonium conjugated poly(ε-caprolactone)-based self-assembled nanostructures as nano-sized drugs and drug delivery carriers for mitochondria-targeting synergistic anticancer drug delivery. Adv Funct Mater2015; 25(34): 5479–5491.
192.
WangFSunWLiL, et al.Charge reversible multifunctional HPMA copolymers for mitochondrial targeting. ACS Appl Mater Inter2017; 9(33): 27563–27574.
193.
SongXPKongXHeSF, et al.Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents. Eur J Med Chem2017; 138: 246–254.
194.
ShibataS.. A drug over the millennia: Pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi2000; 120(10): 849–862.
195.
SharmaGKarSPalitS, et al.18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO 3a/Bim pathway in human breast cancer MCF-7 cells. J Cel Physiol2012; 227(5): 1923–1931.
196.
LeeCSKimYJLeeMS, et al.18-β glycyrrhetinic acid induces apoptotic cell death in siHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Life Sci2008; 83(13–14): 481–489.
197.
YangJCMyungSCKimW, et al.18β-glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway. Mol Cel Biochem2012; 370(1–2): 209–219.
198.
ChenZZhangLSongY, et al.Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery. Biomaterials2015; 52: 240–250.
199.
ZhangCWangWLiuT, et al.Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials2012; 33(7): 2187–2196.
200.
ZhangCLiuZZhengY, et al.Glycyrrhetinic acid functionalized graphine oxide for mitochondria targeting and cancer treatment in vivo. Small2018, DOI: 10.1002/small.201703306.
201.
LiuYZhouZLinX, et al.Enhanced reactive oxygen species generation by mitochondria targeting of anti-cancer drug to overcome tumor multidrug resistance. Biomacromol2019; 20(10): 3755–3766.
202.
ZhouMLiLLiL, et al.Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharm Sin B2019; 9(3): 615–625.
203.
WisnovskySPWilsonJJRadfordRJ, et al.Targeting mitochondrial DNA with a platinum-based anti-cancer agent. Chem Biol2013; 20(11): 1323–1328.
204.
AbeJYamadaYHarashimaH. Validation of a strategy for cancer therapy: Delivering aminoglycoside drugs to mitochondria in hela cells. J Pharm Sci2016; 105(2): 734–740.
205.
SatoYNakamuraTYamadaY, et al.Development of a multifunctional envelop-type nano device and its application to nanomedicine. J Control Release2016; 244: 194–204.
206.
VarbiroGVeresBGallyasFJ, et al.Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med2001; 31(4): 548–558.
207.
MironovSLIvannikovMVJohanssonM. [Ca2+] i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules from mitochondrial permeability transition pore to Ca2+-induced Ca2+ release. J Biol Chem2005; 280(1): 715–721.
208.
YamadaYHarashimaH. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial disease. Adv Drug Deliv Rev2008; 60(13–14): 1439–1462.
209.
WeberTDalenHAnderaL, et al.Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with antineoplastic activity: Comparison with receptor-mediated pro-apoptotic signaling. Biochem2003; 42(14): 4277–4291.
210.
DongLFLowPDyasonJC, et al.α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene2008; 27(31): 4324–4335.
211.
LiuYLiQXiongX, et al.Mitochondria-targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of α-tocopheryl succinate. J Mater Chem B2018; 6(46): 7674–7683.
212.
YangYZhouZHeS, et al.Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Flurouracil conjugated. Biomater2012; 33(7): 2260–2271.
213.
YangYLiLZhouZ, et al.Targeting prostate carcinoma by G3-C12 peptide conjugated N-(2-hydroxypropyl) methacrylamide copolymers. Mol Pharm2014; 11(10): 3251–3260.
214.
SunWLiLYangQ, et al.G3-C12 peptide reverses Galectin-3 from foe to friend for active targeting cancer treatment. Mol Pharm2015; 12(11): 4124–4136.
215.
WangXXLiYBYaoHJ, et al.The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-dis-tearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomater2011; 32(24): 5673–5687.
216.
YuYWangZHZhangL, et al.Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomater2012; 33(6): 1808–1820.
217.
MaPChenJBiX, et al.Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox sensitive paclitaxel release. ACS Appl Mater Inter2018; 10(15): 12351–12363.
218.
WangHGaoZLiuX, et al.Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance. Nat Commun2018; 9(1): 562.
219.
WangYYangFZhangHX, et al.Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis2013; 4: e783.
220.
HuoDZhuJChenG, et al.Eradication of unresectable liver metastasis through induction of tumor specific energy depletion. Nat Commun2019; 10(1): 3051.
221.
MarracheSTundupSHarnDA, et al.Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano2013; 7(8): 7392–7402.
222.
ChenQDuYZhangK, et al.Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer’s disease. ACS Nano2018; 12(2): 1321–1338.
223.
WuHLiFShaoW, et al.Promoting angiogenesis in oxidative diabetic wound microenvironment using a nanozyme-reinforced self-protecting hydrogel. ACS Cent Sci2019; 5(3): 477–485.
224.
TianBPLiFLiR, et al.Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis. Biomater2019; 192: 429–439.
225.
MulikRSMonkkonenJJuvonenRO, et al.ApoE3 mediated polymeric nanoparticles containing curcumin: Apoptosis induced in vitro anticancer activity against neuroblastoma cells. Int J Pharm2012; 437(1–2): 29–41.
226.
OnoKHasegawaKNaikiH, et al.Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res2004; 75(6): 742–750.
227.
BlaikieFHBrownSESamuelssonLM, et al.Targeting dinitrophenol to mitochondria: Limitations to the development of a self-limiting mitochondrial protonophore. Biosci Rep2006; 26(3): 231–243.
228.
FloridiAPaggiMGMarcanteML, et al.Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst1981; 66(3): 497–499.
229.
NeuzilJDyasonJCFreemanR, et al.Mitocans as anti-cancer agents targeting mitochondria: Lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr2007; 39(1): 65–72.
230.
MandalAK. Zinc oxide nanoparticles as delivery system to combat diseases. Int J Curr Adv Res2018; 7(5D): 12469–12478.
231.
MandalAKDasN. Sugar coated liposomal flavonoid: A unique formulation in combating carbontetrachloride induced hepatic oxidative damage. J Drug Target2005; 13(5): 305–315.
232.
MandalAK. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int J Polym Mater Polym Biomater2021; 70(4): 287–297.
233.
MandalAK. Melatonin as potent therapeutic drug in vesicular delivery application in combating diseases. Glob J Nanomed2021; 5(4): 555669.
234.
MandalAKJoardarA. Manganese nanomaterials as delivery system in combating diseases. Int J Curr Res2021; 13(10): 19306–19315.
